Full-Time
Operations Finance Senior Manager
Updated on 8/24/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
 Accounting (1) |
|---|
Get referred to Amgen
See people who can refer or advise you
- Strong expertise in Operations and Corporate Finance, accounting principles, budgeting, forecasting, variance analysis, and strategic financial decision support.
- Experience serving as a finance partner to operations, finance, and cross-functional business leaders.
- Ability to use financial systems and reporting tools such as SAP, Hyperion, Anaplan, Excel, Smartsheet, and S/4HANA.
- Ability to communicate financial results, risks, opportunities, and recommendations clearly to senior finance leaders and business partners.
- Lead financial planning, budgeting, forecasting, and long-range planning activities for Operations Finance.
- Oversee monthly and quarterly financial reporting, including variance analysis, trend analysis, executive-level commentary, and business performance insights.
- Serve as a strategic finance partner to Operations stakeholders by translating business drivers, cost trends, risks, and opportunities into actionable financial recommendations.
- Manage expense planning, cost center analysis, headcount tracking, capital planning, and other key operational finance activities.
- Analyze actual results versus budget, forecast, and prior periods; identify key variances, explain business drivers, and recommend corrective actions where appropriate.
- Lead the preparation of management presentations, financial summaries, business reviews, and executive decision-support materials.
- Oversee month-end and quarter-end close activities, including accrual review, journal entry support, account reconciliations, and financial validation.
- Ensure financial discipline and compliance with accounting policies, internal controls, and corporate finance requirements.
- Collaborate with Finance, Accounting, Supply Chain, Manufacturing, Procurement, and other business partners to support operational and strategic decision-making.
- Identify, lead, and implement opportunities to improve financial processes, reporting consistency, forecast accuracy, and overall finance effectiveness.
- Lead ad hoc financial analysis, scenario modeling, investment evaluation, and business case development for operational initiatives.
- Leverage financial systems and reporting tools to drive accurate analysis and reporting.
- Communicate financial results, risks, opportunities, and recommendations clearly to senior finance leaders and business partners.
- Provide coaching, guidance, and review support to finance team members, helping build analytical capability and ensure high-quality deliverables.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
- Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
- Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.
What critics are saying
- FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
- Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
- Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.
What makes Amgen unique
- Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
- MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
- Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.
Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.
Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.
Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.
Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.